- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00322803
ELB139 Given Orally to Patients With Concurrent Panic Disorder, Challenged by CO2 Inhalation After a Single Dose and One Week of Treatment
September 27, 2006 updated by: elbion AG
International, Multicenter, Randomized, Double-Blind, Placebo Controlled, Two-Period, Cross-Over Study to Demonstrate Safety, Tolerability and Anxiolytic Effects of 600 mg ELB139 Given Orally t.i.d. to Patients With Concurrent Panic Disorder, Challenged by Inhalation of 35% CO2 After a Single Dose and One Week of Treatment
This study is designed to investigate if 600 mg ELB139 given orally t.i.d. to patients suffering from panic disorder is effective in reducing anxiety evoked by inhalation of 35% CO2 measured by a visual analogue scale after the first intake and after approximately one week of treatment as compared to placebo treatment.
Study Overview
Study Type
Interventional
Enrollment
24
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Berlin, Germany, 10117
- Charité - University Clinics Berlin
-
Berlin, Germany, 10629
- Emovis, The institute of emotional health
-
-
-
-
-
Maastricht, Netherlands, 6200 MD
- Academic Anxiety Center and Department of Psychiatry & Neuropsychology; Maastricht University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of concurrent panic disorder
- At least 2 panic attacks within the 4 weeks before the screening visit
- Naïve to the CO2 challenge test
- Age 18-65 years (inclusive)
- Ability to comply with all procedures mandated by the study protocol
- Negative pregnancy test and adequate contraceptive measures
Exclusion Criteria:
- History of poly-pharmacotherapy for panic disorder or treatment resistance
- Any current psychiatric Axis I DSM-IV diagnosis other than panic disorder, except concurrent simple phobia
- History of abuse of benzodiazepines or tolerance to effects of benzodiazepine
- Any concomitant psychotropic medication
- Evidence of impaired hepatic, renal or cardiac functions
- Participation in any drug trial in the preceding 6 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
degree of subjective anxiety as measured on a Visual Analogue Scale for Anxiety(VAS-A) assessed immediately after the CO2-challenge (VAS-A-post)
|
difference of the degree of anxiety measured as the difference between the pre- and post challenge scores on the Visual Analogue Scale for Anxiety (VAS-A-delta)
|
Secondary Outcome Measures
Outcome Measure |
---|
Total Symptom Score assessed immediately after CO2 challenge (TSS-post)
|
Difference of the Total Symptoms Score (TSS) measured as the difference between the pre- and post challenge scores (TSS-delta)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Eric Griez, Prof Dr, Academic Anxiety Center and Department of Psychiatry & Neuropsychology; Maastricht University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2006
Study Completion
October 1, 2006
Study Registration Dates
First Submitted
May 5, 2006
First Submitted That Met QC Criteria
May 5, 2006
First Posted (Estimate)
May 8, 2006
Study Record Updates
Last Update Posted (Estimate)
September 29, 2006
Last Update Submitted That Met QC Criteria
September 27, 2006
Last Verified
September 1, 2006
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Anxiety Disorders
- Disease
- Panic Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Tranquilizing Agents
- Psychotropic Drugs
- Anti-Anxiety Agents
- GABA Agents
- Anticonvulsants
- GABA-A Receptor Agonists
- GABA Agonists
- 1-(4-chlorophenyl)-4-piperidin-1-yl-1,5-dihydroimidazol-2-one
Other Study ID Numbers
- ELB139202-05
- EudraCT Number:2005-005708-17
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Panic Disorder
-
Philipps University Marburg Medical CenterGerman Federal Ministry of Education and ResearchCompletedPanic Disorder With Agoraphobia | Panic Disorder Without AgoraphobiaGermany
-
Beth Israel Medical CenterTerminatedPanic Disorder | Major Depressive Disorder With Panic AttacksUnited States
-
Ulrike WillutzkiUnknownDepression | Panic Disorder | Agoraphobia | Panic Disorder With Agoraphobia | Agoraphobia With Panic AttacksGermany
-
Charite University, Berlin, GermanyRecruitingGeneralized Anxiety Disorder | Social Anxiety Disorder | Panic Disorder With Agoraphobia | Panic Disorder Without AgoraphobiaGermany
-
Southern Methodist UniversityBoston University; University of MichiganCompletedPanic Disorder With AgoraphobiaUnited States
-
Karolinska InstitutetCompleted
-
Beth Israel Medical CenterCompletedPanic Disorder | Major Depression With Panic AttacksUnited States
-
Region SkaneCompletedPanic Disorder (With or Without Agoraphobia)Sweden
-
Michael E. DeBakey VA Medical CenterSouth Central VA Mental Illness Research, Education & Clinical CenterUnknown
-
Ruhr University of BochumTerminatedPanic Disorder With AgoraphobiaGermany